Article Text

Download PDFPDF
Recent updates from the BNF

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some of the key changes that have been made to BNF content since the last print edition (BNF 77) was published.

New monographs

Ertugliflozin (Steglatro)

A new addition to the sodium-glucose co-transporter 2 (SGLT2) inhibitors family, for the treatment of type 2 diabetes mellitus in adults, either as monotherapy (if metformin is deemed inappropriate due to intolerance or contra-indications) or in combination with insulin or other antidiabetic drugs if existing treatment fails to achieve adequate glycaemic control.

Hypoglycaemia is a side effect of ertugliflozin when used in combination with insulin or a sulfonylurea. Therefore, concomitant insulin or drugs that stimulate insulin secretion may require dose reduction.

A drug safety update from the Medicines and Healthcare products Regulatory Agency (MHRA)/Commission on Human Medicines (CHM) reports Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum), a rare but serious and potentially life-threatening infection with SGLT2 inhibitors. For further information please visit:

Insulin glargine with lixisenatide (Suliqua)

A novel medicinal combination containing a long-acting recombinant human insulin analogue and a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist …

View Full Text